Close
Close

Pipeline

Focused Indication Program Modality Molecule / Product Discovery / Preclinical Clinical Development Approved / Launched
Hera-203
Diagnostic
Innovative
Non-invasive Diagnostic
Hera-003
Drug
Innovative
Non-hormonal Therapeutic mAb
Hera-201
Diagnostic
Innovative
Endometrial Receptivity Analysis Test
Hera-210
Diagnostic and Device
Innovative
Oocyte Quality Test + Oocyte Quality Improvement Device
Hera-001
Drug
Innovative
Non-antibiotic, Engineered Bacteria
Focused Indication Program Modality Molecule / Product Commercial Right Launched
子宫内膜异位症(Endo)
Hera-203
Diagnostic
Innovative
Non-invasive Diagnostic
Greater China
2023 (LDT)
2028 (IVD)
Hera-003
Drug
Innovative
Non-hormonal Therapeutic mAb
Global
2030 (BLA)
Infertility
Hera-201
Diagnostic
Innovative
Endometrial Receptivity Analysis
Greater China
Launched (LDT)
Hera-210
Diagnostic and Device
Innovative
Oocyte Quality Test + Oocyte Quality Improvement Device
APAC *
Launched (HK LDT)
2029 (IVD)
细菌性阴道炎(BV)
Hera-001
Drug
Innovative
Non-antibiotic, Engineered Bacteria
Global
2030 (NDA)
* Can be expanded to US and EU
zh_CN